Blood test strategy aims to cut TB treatment dropouts

NCT ID NCT06590428

Recruiting now Disease control Sponsor: Albert Einstein College of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether regularly measuring linezolid levels in the blood can prevent dangerous side effects and keep people on their tuberculosis treatment. About 280 adults with rifampin-resistant TB will be randomly assigned to either standard care or dose adjustments based on drug levels. The goal is to reduce treatment interruptions and improve outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: linezolid
What this could lead to: If successful, this approach could help more people complete their TB treatment without dangerous side effects, improving cure rates.
What could go wrong: This is a pragmatic trial, not a new drug. The monitoring strategy may not significantly reduce side effects or may be too complex for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG-RESISTANT TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

drug-resistant tuberculosis multidrug-resistant tuberculosis rifampicin-resistant tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRUG-RESISTANT TUBERCULOSIS RIFAMPIN-RESISTANT TUBERCULOSIS

Contacts and locations

Locations

Nkqubela TB Specialist Hospital
RECRUITING

East London, Eastern Cape, 5206, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.